key: cord-0792423-hl284v4g
authors: Fujita, Ryosuke; Hino, Masato; Ebihara, Takeru; Nagasato, Takumi; Masuda, Akitsu; Lee, Jae Man; Fujii, Tsuguru; Mon, Hiroaki; Kakino, Kohei; Nagai, Ryo; Tanaka, Miyu; Tonooka, Yoshino; Moriyama, Takato; Kusakabe, Takahiro
title: Efficient production of recombinant SARS-CoV-2 spike protein using the baculovirus-silkworm system
date: 2020-06-09
journal: Biochem Biophys Res Commun
DOI: 10.1016/j.bbrc.2020.06.020
sha: b3ef20fe5df3902c29bfa9247465649869fd61cd
doc_id: 792423
cord_uid: hl284v4g

In the case of a new viral disease outbreak, an immediate development of virus detection kits and vaccines is required. For COVID-19, we established a rapid production procedure for SARS-CoV-2 spike protein (S protein) by using the baculovirus-silkworm expression system. The baculovirus vector-derived S proteins were successfully secreted to silkworm serum, whereas those formed insoluble structure in the larval fat body and the pupal cells. The ectodomain of S protein with the native sequence was cleaved by the host furin-protease, resulting in less recombinant protein production. The S protein modified in furin protease-target site was efficiently secreted to silkworm serum and was purified as oligomers, which showed immunoreactivity for anti-SARS-CoV-2 S2 antibody. By using the direct transfection of recombinant bacmid to silkworms, we achieved the efficient production of SARS-CoV-2 S protein as fetal bovine serum (FBS)-free system. The resultant purified S protein would be useful tools for the development of immunodetection kits, antigen for immunization for immunoglobulin production, and vaccines.

In the case of a new viral disease outbreak, an immediate development of virus 2 detection kits and vaccines is required. For COVID-19, we established a rapid production 3 procedure for SARS-CoV-2 spike protein (S protein) by using the baculovirus-silkworm 4 expression system. The baculovirus vector-derived S proteins were successfully secreted to 5 silkworm serum, whereas those formed insoluble structure in the larval fat body and the pupal 6 cells. The ectodomain of S protein with the native sequence was cleaved by the host 7 furin-protease, resulting in less recombinant protein production. The S protein modified in furin 8 protease-target site was efficiently secreted to silkworm serum and was purified as oligomers, 9 which showed immunoreactivity for anti-SARS-CoV-2 S2 antibody. By using the direct 10 transfection of recombinant bacmid to silkworms, we achieved the efficient production of 11 SARS-CoV-2 S protein as fetal bovine serum (FBS)-free system. The resultant purified S 12 protein would be useful tools for the development of immunodetection kits, antigen for 13 immunization for immunoglobulin production, and vaccines. 14 Introduction 21

Coronavirus disease 2019 was outbreaking in December 2019, and it 22 rapidly spread worldwide in early 2020 [1] . The pathogen of COVID-19 is a novel coronavirus 23 designated as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The genetic 24 sequence of SARS-CoV-2 was immediately released in January 2020 [2] , and many researchers 25

The serum samples were recovered as described above. The fat bodies of infected 2 larvae were homogenized in buffer (20 mM Tris-HCl (pH7.5), 500 mM NaCl), then sonicated 3 for 10 min. The homogenized samples were centrifuged (9,000 rpm, 30 min., 4°C), and the 4 supernatants and pellets were recovered as soluble and insoluble fractions, respectively. For the 5 analysis of pupae, the homogenates were prepared at four d.p.i. Briefly, three pupae were 6 homogenized in lysis buffer (20 mM Tris-HCl (pH7.5), 500 mM NaCl, 0.5% CHAPS), 7 sonicated, and centrifuged with the same protocol for fat bodies. 8 The sample was separated in 8%, 7.5%, or 5-20% SDS-PAGE. The gels were stained 9 by the reverse stain method. Briefly, the gels were rinsed in distilled water (DW) then incubated 10 in the solution I (200 mM imidazole, 0.1% SDS) for 10 minutes. The gel was then incubated 11 with solution II (200 mM ZnSO 4 ) for 2 min, then rinsed with DW. After imaging, the gel was 12 destained by rinsed in 100 mM ethylenediaminetetraacetic acid (ETDA) for 15 min, then used 13 for western blotting. 14 The proteins in the gel were blotted on PVDF membrane, then incubate with 15

Tris-buffered saline with 0.1% Tween 20 (TBST) containing 4% skim milk. The membrane was 16 rinsed in TBST then incubated with anti-SARS-CoV-2 Spike S2 antibody (Sino Biological Inc.). 17 Anti-rabbit IgG HRP-conjugated antibody was used as a secondary reaction, and the signals 18 were visualized using Super Signal West Pico Chemiluminescent Substrate (Thermo Scientific). 19 20 

The samples were mixed with 1/5 volume of native sample buffer (250mM Tris-HCl 22 (pH 6.8), 0.1% BPB, 40% glycerol), and loaded on the 5-20% gradient gel without 23 heat-denaturing. The proteins were separated in PAGE with native running buffer (25 mM Tris 24 and 192 mM glycine) at 4°C. The gel was subjected to reverse staining and western blotting, as 6 described above. For the production of candidate recombinant vaccine molecules for SARS coronavirus 4 2, it is desirable to use the eukaryote system without using fetal bovine serum (FBS). Therefore, 5 we decided to apply the BmNPV-silkworm expression system without using cultured cells [18] . 6 We first determined the efficiency of progeny production of recombinant BmNPV in our 7 method (Fig. 1 ). The recombinant bacmid carrying GFP gene was transfected to 4th-instar 8 larvae of silkworms. At 4-days post-transfection, the silkworms showed GFP expression in the 9 whole body, especially strong fluorescence in head and tail leg regions (Fig. 1B) . The progeny 10 viruses (P1 viruses) were recovered from 4 d.p.t. (approximately 100 μl serum from one larva), 11 then ten μl of the diluted series of the P1 viruses were inoculated into day 2 of 5th-instar larvae 12 (6-days after the first transfection). At 2-days post-infection, all the infected larvae showed GFP 13 fluorescence even with the 1×10 5 dilution of P1 viruses (Fig. 1B) . Thus, our method achieved 14 efficient production (more than 1×10 5 shots from one larva) of recombinant BmNPV before the 15 same reared series of silkworms reached to the 5th-instar stage. 16 We then constructed recombinant BmNPV bacmid carrying the extracellular domain 17 of the SARS-CoV-2 spike gene. The spike protein of coronavirus has been known to form the 18 trimeric structure on the surface of the virion. We introduced the β-sheet domain of CELO long 19 fiber knob with an expect to facilitate oligomerization [19] . The expected molecular size of the 20 designed recombinant nCoV-S protein was 141 kDa, including peptide tags (Fig. 1C) . 21 We then transfected the recombinant bacmid into 4th-instar larvae and infected P1 22 progeny viruses to 5th-instar larvae of silkworms as described above. In the SDS-PAGE and 23 western blotting analysis, we could see the expression of nCoV-S in the silkworm serum as a 24 secreted protein, however, the amount of expressed recombinant protein was not so much in 25 comparison of other background proteins ( Fig. 2A, left) . In the fat bodies of the infected larvae, 1 the recombinant protein appeared as an insoluble fraction with a smeared pattern ( Fig. 2A,  2 center). It was also the same in the analysis of the infected pupae ( Fig. 2A right) . Thus, the 3 recombinant nCoV-S was secreted to blood but seemed to form aggregates with some 4 degradation in the fat bodies and pupal cells. 5

It has been known that the S protein of SARS-CoV-2 possesses the furin 6 protease-recognition site [20] . Silkworm Bombyx mori encodes some putative furin protease 7 genes in its genome (Accession: PRJNA205630). We considered that the expressed 8 SARS-CoV-2 S protein was targeted by endogenous furin proteases, which worsened the 9 recombinant protein secretion. Therefore, we constructed another recombinant virus with 10 modification in the furin protease-recognition site according to Wrapp's method [7] . We could 11 detect the significant signal in the serum fraction with the expected molecular size in the 12 expression analysis for the larval blood (Fig. 2B) . However, the recombinant protein still 13 formed an insoluble structure in the fat bodies and the pupal cells. 14 So far, the recombinant proteins were secreted in serum as soluble proteins. We 15 conducted an affinity chromatography purification for these proteins. In the purification nCoV-S 16 with Ni-sepharose column, some ladder pattern was found around 140 kDa molecular size, 17 especially in elution-1 fraction (100 mM imidazole) (Fig. 3, left) . The ladder pattern was 18 moderate in elution-2 (500 mM imidazole), suggesting that the ladder pattern around 140 kDa 19 was the background proteins. Therefore, we carried out subsequent Strep-Tactin column 20 purification for elution-1 and -2 of His-tag purification, respectively. The results showed that the 21 purified protein bands were not visible in the SDS-PAGE image but found in western blotting 22 using anti-SARS-CoV-2 spike S2 antibody (Fig. 3, center and right) . In the Strep-tag 23 purification of His-tag column elution-1, we could see two bands (approximately 140 kDa and 24 1 signal in the purified fraction from the His-tag elution-2 sample. 2 We then tried to purify the nCoV-S NF protein, which was expected not to targeted by 3 furin protease. In the Ni-sepharose purification, we could detect the possible recombinant 4 protein bands around 140 kDa molecular weight, although other background proteins appeared 5 (Fig. 4A, left) . In the subsequent Strep-Tactin sepharose column purification, we could see the 6 fine bands in elution fractions with expected molecular size ( Fig. 4A ; center and right). The 7 western blotting analysis revealed that the eluates were surely the nCoV-S recombinant proteins. 8 Interestingly, we still found the anti-SARS coronavirus S2 antibody-reactive protein with the 9 size of 70 kDa, although the furin-target site was not in the recombinant protein. 10 The recombinant nCoV-S protein without furin-target sequence was found to be 11 purified in our method with possessing the reactivity for the SARS-CoV-2 spike S2 antibody in 12 denatured PAGE. The purified nCoV-S NF (elution-A and -B in Fig. 4A ) were subjected to 13 native PAGE analysis (Fig. 4B) . The proteins appeared as broad bands around 700 kDa, and 14 those were immunoreactive for anti S2 antibody. On the other hand, no significant signals were 15 found around the molecular size marker of 146 kDa, which was considered to be the size of the The estimated value of the purified protein from 10 ml serum (corresponding to 30-40 larvae) 21 was about 100 μg. For a rapid and efficient production of recombinant proteins using the BmNPV-silkworm system, steps of the production of recombinant viruses and the silkworm 1 rearing schedule are sometimes to be a bottleneck. To overcome this issue, we designed the plan 2 to generate the recombinant BmNPV in 4th-instar larvae and express recombinant proteins in 3 the following 5th-instar larvae (Fig .1A) . The method enables us to purify the recombinant 4 proteins within ten days from the construction of recombinant bacmid, which is completed in 5 the same rearing series of silkworms. Because the production of the recombinant P1 virus 6 reached to more than 1×10 5 shots from 1μg of the extracted bacmid DNA (containing helper 7 plasmids and pFastBac plasmids), it is easy to expand the production scale with the same 8 schedule. Our method presented here was an FBS-free method, which could keep cost low and 9 avoid pathogen contamination from FBS. 10 We first tried to express the ectodomain of SARS-CoV-2 S protein with the native 11 sequence; however, the purified protein was less, and the S protein seemed to be cleaved. 12 Recent studies demonstrated that SARS-CoV-2 possesses a furin protease-cleavage site in its 13 spike gene [7] [8] [9] 11, 20] . In the BEVS using Sf9 cells, the expressions of the ectodomain of 14 SARS-CoV-2 S protein seemed to be successful, although the native sequence of S protein was 15 partially affected by furin proteases. On the other hand, most of the recombinant nCoV-S 16 protein in the silkworm seemed to be processed by furin protease ( Fig. 2A and 3 ). Because the 17 cleavage by furins is a proprotein processing, the expressed nCoV-S was digested in the cells, 18 resulting in the loss of N-terminal signal peptide from the C-terminal half of S protein (S2 19 domain). According to this idea, the truncated form of S2 protein could not be secreted to 20 silkworm serum, so we could not find enough nCoV-S in the extracted silkworm serum. Indeed, 21 S protein without furin cleavage site (nCoV-S-NF) was successfully appeared in the silkworm 22 serum (Fig. 2B) , supporting the above idea. Although the intact form of nCoV-S-NF was 23 purified, we also found the digested protein (about 70 kDa), including the S2 domain (Fig. 4) . 24 The S protein of SARS-CoV-2 possesses another proteolytic site called S2´ (aa 814-817), which is conserved among human-related coronaviruses [20, 21] . Therefore, the digested protein found 1 in the purified nCoV-S-NF fraction with the size of 70 kDa was considered to be an S2´-cleaved 2 protein. It was also possible that the digested protein was a furin-cleaved protein with less 3 digestion activity, although the details have not been clear so far. Because S protein of 4 SARS-CoV-S is considered to be a glycoprotein and has multiple glycosylation sites in its 5 amino acid sequence [22] , the size of nCoV-S and its cleaved protein would appear at the 6 position higher than the estimated sizes (intact nCoV-S = 141 kDa, furin-cleaved S2 = 64 kDa, 7 S2´-cleaved S2 = 50 kDa). The furin-cleavage site of S protein is considered to be a unique 8 feature of SARS-CoV-2 and might function in its infectivity [8, 9, 21] . For the production of 9 mature S2 protein in silkworm, one possible idea is a construction of S2 protein with directly 10 connecting signal peptides in its N-terminal region. For the production of the entire ectodomain 11 of S protein without mutation in the furin-cleavage site, it is required to repress the furin activity 12 in silkworms, although it has been unclear which and how many furin proteases function in 13 silkworms. 14 In the affinity chromatography of nCoV-S-NF using the Ni-sepharose column, the 15 recombinant proteins were separated in elution-1 (containing 100 mM imidazole) and elution-2 16 (containing 500 mM imidazole) (Fig. 4) . The denatured PAGE showed that the purified proteins 17 that came from those two fractions showed almost the same in size, suggesting that the 18 components of those fractions consist of the same molecules. On the other hand, the Native 19 PAGE image showed that the significant signals appeared in almost the same position, but the 20 size of lower bands was different. These implied that the secreted nCoV-S-NF formed some 21 different complexes. It might include heterooligomer with a cleaved S2 domain. 22 In the fat body of infected larvae and the infected pupal cells, nCoV-S was insoluble 23 and appeared as the smeared bands in the PAGE and western blot images (Fig. 2A) . The 24 estimated size of the smeared patterns ranged around 100 kDa, suggested that the nCoV-S was 25 degraded and formed an insoluble complex with other host proteins in the larval fat body and 1 pupal cells. The furin protease would contribute to this degradation because the size of the 2 insoluble protein was larger in nCoV-S-NF, although they still showed smeared pattern in the 3 western blot images (Fig. 2B) . 4 We successfully purified the ectodomain of SARS-CoV-2 S protein as a secreted 5 oligomer protein. Because the purified nCoV-S-NF was immunoreactive even in the native page, 6 it will be a useful tool for the development of immunodetection kits, antigen for immunization, 7 and also vaccines. 

-Establishment of the BmNPV-silkworm expression system for production of the ectodomain of SARS-CoV-2 spike protein.

-The SARS-CoV-2 S protein with the native sequence was cleaved by the host silkworm furin protease.

-S protein without furin-cleavage site could be purified as oligomeric structures with immunoreactivity to the anti-SARS-CoV-2 S2 antibody.

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☐ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Please note that all Biochemical and Biophysical Research Communications authors are required to report the following potential conflicts of interest with each submission. If applicable to your manuscript, please provide the necessary declaration in the box above.

(1) All third-party financial support for the work in the submitted manuscript.

(2) All financial relationships with any entities that could be viewed as relevant to the general area of the submitted manuscript.

(3) All sources of revenue with relevance to the submitted work who made payments to you, or to your institution on your behalf, in the 36 months prior to submission. (4) Any other interactions with the sponsor of outside of the submitted work should also be reported. (5) Any relevant patents or copyrights (planned, pending, or issued). (6) Any other relationships or affiliations that may be perceived by readers to have influenced, or give the appearance of potentially influencing, what you wrote in the submitted work. As a general guideline, it is usually better to disclose a relationship than not.

Coronavirus diseases (COVID-19) pandemic, WHO

The Challenges of Vaccine Development against a

New Virus during a Pandemic

Development of a rapid test kit for SARS-CoV-2: an 7 example of product design

SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of infection

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Cell entry mechanisms 21 of SARS-CoV-2

Structural basis of receptor recognition by SARS-CoV-2

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2

Structural and Functional Basis of SARS-CoV

Entry by Using Human ACE2

Expression of the thermostable Moloney murine 14 leukemia virus reverse transcriptase by silkworm-baculovirus expression system

Expression and purification of biologically active human 18 granulocyte-macrophage colony stimulating factor (hGM-CSF) using

silkworm-baculovirus expression vector system

Purification and characterization of immunogenic 23 recombinant virus-like particles of porcine circovirus type 2 expressed in silkworm Hamdan

Recombinant Thermococcus kodakaraensis (KOD) DNA Polymerases Produced Using

Expression Vector System

Efficient and cost effective production 7 of active-form human PKB using silkworm larvae

Fiber knob domain lacking the shaft sequence but fused to a coiled coil is a 11 candidate subunit vaccine against egg-drop syndrome

The spike 14 glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site 15 absent in CoV of the same clade